Drug effective in preventing stroke, reducing bleeding, cardiovascular death in patients with atrial fibrillation

A late-breaking clinical trial demonstrates that high- and low-dose edoxaban were at least as effective in preventing stroke or systemic embolism (blood clot), while significantly reducing bleeding and cardiovascular death, compared to warfarin.